4/A: Director Plans Future GALT Stock Purchase

Galectin Therapeutics Director Kevin D. Freeman reported a planned acquisition of 5,500 shares of common stock at $3.548 per share on December 23, 2025.

Summary

• Director Kevin D. Freeman of Galectin Therapeutics Inc. reported a planned acquisition of 5,500 shares of common stock.
• The transaction is scheduled for December 23, 2025, at a price of $3.548 per share.
• This purchase is being made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
• Following this planned transaction, Mr. Freeman will directly own 55,269 shares.
• He will also indirectly own 80,000 shares through Freeman Global Holdings LLC and 18,063 shares through an IRA, bringing his total beneficial ownership to 153,332 shares.
• This Form 4/A is an amendment to an original filing also dated December 23, 2025.

Sentiment

Score: 7

Explanation: A director's pre-planned future purchase of company stock under a 10b5-1 plan generally indicates a long-term positive outlook and confidence in the company's future, which is a positive signal for investors.

Positives

• A director's commitment to purchase company stock in the future, especially under a 10b5-1 plan, can signal confidence in the company's long-term prospects.
• The transaction is pre-planned under Rule 10b5-1(c), which provides an affirmative defense against insider trading allegations, indicating a structured investment approach.

Future Outlook

This filing reports a pre-planned future transaction by a director and does not contain explicit forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

Insider purchases, particularly by directors, are generally viewed as a positive signal in the market, suggesting that those with intimate knowledge of the company believe its stock is undervalued or has strong long-term potential. This type of activity is common across various industries and can influence investor sentiment.

Comparison to Industry Standards

• Insider buying activity, especially by directors, is generally viewed favorably by investors as it aligns management's interests with shareholders.
• While the specific amount of shares planned for purchase (5,500) is relatively small compared to the total outstanding shares of a publicly traded company, it represents a direct investment commitment by a key insider.
• Without specific industry benchmarks for insider buying volume, it is difficult to compare this transaction directly to peers. However, the act of a director planning to buy shares is inherently a positive indicator of confidence.

Related Party Transactions

• Indirect beneficial ownership of 80,000 shares through Freeman Global Holdings LLC, an entity controlled by the reporting person.

Stakeholder Impact

• Shareholders: May view the director's planned purchase as a positive signal, potentially increasing confidence in the stock's long-term value.

Key Dates

Recommendation

A director's pre-planned future purchase of company stock, while a positive signal of long-term confidence, does not provide immediate new information about the company's current performance or strategic direction. This Form 4/A filing reports a future transaction under a 10b5-1 plan. Investors should consider this alongside broader financial performance, strategic developments, and market conditions before making investment decisions. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while monitoring further developments.

Keywords

Galectin Therapeutics, GALT, Insider Trading, Director Purchase, Stock Acquisition, Form 4, Kevin D. Freeman, Beneficial Ownership, Rule 10b5-1